Genmab and Seagen Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin Biologics License Application for Patients with Recurrent or Metastatic Cervical Cancer

COPENHAGEN, Denmark and BOTHELL, Wash.; April 09, 2021– Genmab A/S (Nasdaq: GMAB) and Seagen Inc. (Nasdaq: SGEN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news